Svmuu News U.S. House Financial Services Committee Chairman French Hill stated that the CLARITY Act is expected to address some regulatory issues not yet covered by the GENIUS Act. In an interview, Hill mentioned that the banking industry still has concerns about the proposed crypto regulatory framework, particularly regarding how crypto companies might be regulated in the future.
Hill pointed out that the House passed the CLARITY Act with bipartisan support last summer, including 78 Democratic lawmakers voting in favor. The bill is part of Washington's push to establish a digital asset regulatory system, aiming to clarify how stablecoins and other digital assets operate within the U.S. financial markets.
Furthermore, policymakers are also discussing whether crypto companies should be subject to the same level of regulation as banks. Hill stated that both parties have reached a consensus on a key principle: stablecoins should not pay yields to holders. This issue is also a core topic of discussion surrounding the GENIUS Act.
U.S. House Financial Services Committee Chairman: The CLARITY Act Could Address Regulatory Gaps Left by the GENIUS Act
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
5
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
6
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
7
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
8
MARA Stock Valuation Analysis: Marathon Digital Holdings’ Transition to AI and Long-Term Investment Outlook
-
9
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
10
NVIDIA and AMD: The Two Giants of AI Computing Power in 2026—An Analysis of Market Dynamics, Financial Performance, and Opportunities for Transition into Cryptocurrency Mining
Markets Today
Recommended Reading










